The Floor · H.R. 5850 · Committee
To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.
No sponsor archived.
No committee referrals archived.
Path through Congress · started in the House
H.R. 5850 · 118th
Status
Committee
Introduced
Missing date
Committee
Missing date
House floor
Senate floor
Resolving differences
Enrolled
President's desk
Became law
Latest action · Oct 6, 2023
Referred to the Subcommittee on Health.
No recorded roll calls are listed for this bill. Many measures pass by voice vote or unanimous consent without a member-by-member tally. If Congress.gov later shows recorded votes, they will appear here.
Archive built 2026-10-03 from Library of Congress Congress.gov API.